J. Mark FitzGerald

机构：Vancouver Coastal Health, University of British Columbia, University of Toronto, Queen's University, Vancouver Coastal Health Research Institute · ORCID：0000-0002-5367-5226

发表论文 139 篇 · 总被引 9100 次 · h-index 38

代表论文

• Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes (2021 · European Respiratory Journal · 被引 555)
• Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies (2017 · The Lancet Respiratory Medicine · 被引 322)
• Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma (2018 · European Respiratory Journal · 被引 250)
• Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study (2019 · Clinical Therapeutics · 被引 169)
• Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial (2018 · The Lancet Respiratory Medicine · 被引 134)
• Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes (2021 · The Journal of Allergy and Clinical Immunology In Practice · 被引 132)